Insilico Medicine appoints Dr Feng Ren as co-CEO

Hong Kong and US-based Insilico Medicine, a global clinical-stage artificial intelligence (AI)-powered drug discovery and development company, has announced the appointment of Dr Feng Ren as a coChief Executive Officer (CEO). Dr Ren is currently Insilico Medicine’s Chief Scientific Officer and Head of Global Research and Development. He will retain those titles following the appointment and will also oversee clinical development with full control over discovery, development, and infrastructure. In addition, he will further drive Insilico’s business development in the new role. The appointment solidifies Insilico’s commitment to both artificial intelligence and drug development. Alex Zhavoronkov, Ph.D., will continue to serve as CEO and focus on global expansion and next-generation AI platforms while Dr Ren will drive the company’s drug development efforts. After obtaining a Ph.D. in organic chemistry from Harvard University, Dr Ren spent 15 years in drug discovery and development in the healthcare industry, including with a top multinational pharmaceutical company and a global contract research organisation (CRO). He joined Insilico Medicine from Medicilon, a global CRO, where he served as Senior Vice President and Head of Drug R&D, leading the chemistry and biology departments. Prior to joining Medicilon, Dr Ren served in various drug discovery leadership roles at GlaxoSmithKline (GSK) in both Philadelphia and Shanghai.